성인에서 Palynziq® 치료 중 면역 조절 (IMPALA)
페닐케톤뇨증(PKU) 성인 환자에서 Palynziq® 치료 중 면역 조절에 대한 4상 연구
Study 165-401 is a Phase 4, open-label study designed to examine the concomitant use of methotrexate (MTX) to suppress immune responses to Palynziq and improve tolerability and efficacy in adults with PKU.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The overall objective of the study is to evaluate the ability of MTX, when co-administered with Palynziq, to suppress immune responses to Palynziq and thus improve the tolerability and efficacy of Palynziq in adults with phenylketonuria (PKU). Up to 12 participants will be enrolled into the study across 2 cohorts, with a target enrollment of 6 participants into each cohort:
- Cohort A: Individuals with uncontrolled blood phenylalanine (Phe) > 600 μmol/L on existing management who have never been treated with Palynziq (Palynziq naïve)
- Cohort B: Individuals who have uncontrolled blood Phe > 600 μmol/L after ≥ 24 consecutive weeks of treatment with Palynziq, are on a current dose of≥ 20mg/day, and are unable to further dose escalate (Palynziq experienced)
Palynziq will be initiated (Cohort A) or will continue (Cohort B) as indicated in the Palynziq United States Prescribing Information (USPI) and as prescribed by the participant's treating physician. The decision to initiate or continue Palynziq must be made independently of participation in this study. Palynziq and MTX will not be supplied by BioMarin as part of participation in this study.
All participants will be administered MTX at an oral dose of 15 mg/week concurrent with Palynziq:
- Cohort A participants will have a 4-week Screening Period, followed by a 4-week MTX Tolerability Period during which only MTX will be administered. If MTX is tolerated during the MTX Tolerability Period, the participant will then enter the 24-week Combination Treatment Period during which MTX + Palynziq will be administered concurrently.
- Cohort B participants will have a 4-week Screening Period. Participants will then have 24 weeks of concurrent MTX + Palynziq treatment (Combination Treatment Period): participants will be assessed for MTX tolerability during the first 4 weeks of MTX + Palynziq (MTX Tolerability Period) and then receive another 20 weeks of MTX + Palynziq.
After completion of Week 24 (Combination Treatment Period), MTX will be discontinued for both cohorts and Palynziq only will continue for another 24 weeks (to Week 49; Follow-up Period).
Participants will be assessed for safety and MTX tolerability. If a participant in either Cohort A or B is unable to tolerate MTX, the participant will be discontinued from MTX treatment. Participants who discontinue from MTX early should continue to complete the remaining study assessments until as long as such continued participation will not detrimentally affect the health, safety, and welfare of the participant per investigator determination
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 4단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Trial Specialist
- 전화번호: 1-800-983-4587
- 이메일: medinfo@bmrn.com
연구 장소
-
-
California
-
Los Angeles, California, 미국, 90095
- 모병
- UCLA Dept. of Human Genetics
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- Children's Hospital Colorado
-
-
Florida
-
Tampa, Florida, 미국, 33613
- 모병
- University Of South Florida Medical Center
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 모병
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- 모병
- Indiana University School of Medicine
-
-
Minnesota
-
Minneapolis, Minnesota, 미국, 55455
- 모병
- University of Minnesota Medical School
-
-
New York
-
Rochester, New York, 미국, 14642
- 모병
- University of Rochester Medical Center (URMC)
-
-
Oregon
-
Portland, Oregon, 미국, 97239
- 모병
- Oregon Health & Science University (OHSU) - PARENT
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15224
- 아직 모집하지 않음
- University of Pittsburgh Medical Center (UPMC) - Children's Hospital of Pittsburgh
-
-
Texas
-
Dallas, Texas, 미국, 75390
- 모병
- UT Southwestern Medical Center
-
연락하다:
- Markey McNutt
-
-
Utah
-
Salt Lake City, Utah, 미국, 84108
- 아직 모집하지 않음
- University of Utah Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국, 53226
- 모병
- Children's Hospital of Wisconsin
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Adults between 18 and 65 years old
- Have a confirmed diagnosis of phenylketonuria (PKU)
- Are in generally good health based on medical evaluation
- Are willing and medically eligible to receive Palynziq and methotrexate (MTX) Cohort A: Have never taken Palynziq before and are willing to start it during the study Cohort B: Have blood > 600 μmol/L after taking Palynziq for at least 24 weeks, are on a daily dose of at least 20mg and unable to increase the dose further
- Agree to use required contraception if they or their partner could become pregnant
- Are willing to carry two epinephrine devices at all times during Palynziq treatment
Exclusion Criteria:
- Pregnant, breastfeeding, planning to become pregnant, planning to father a child, or not using effective birth control if applicable
- Have a known severe allergy or hypersensitivity reaction to methotrexate (MTX), Palynziq, or other PEG-containing medications
- Have a serious active infection or a history of severe or recurrent infections
- Have significant medical conditions that may affect safety or participation (such as serious heart, lung, liver, kidney, immune, neurological, psychiatric, or cancer-related conditions)
- Have a history of substance or alcohol abuse within the past 12 months
- Have had an organ transplant or are taking chronic immunosuppressive medications
- Are currently taking medications that are not allowed in the study, including other PKU treatments besides Palynziq
- Are using, or plan to use, injectable PEG-containing medications other than Palynziq during the study
- Have major surgery planned during the study participation period
- Are currently participating in another clinical study involving Palynziq
- In the opinion of the study doctor, are not a suitable candidate for the study or may have difficulty complying with study requirements
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Palynziq naïve
Individuals with uncontrolled blood phenylalanine (Phe) > 600 μmol/L on existing management who have never been treated with Palynziq. Participants will have a 4-week Screening Period, followed by a 4-week MTX Tolerability Period during which only MTX will be administered. If MTX is tolerated during the MTX Tolerability Period, the participant will then enter the 24-week Combination Treatment Period during which MTX + Palynziq will be administered concurrently. After completion of Week 24 (Combination Treatment Period), MTX will be discontinued for both cohorts and Palynziq only will continue for another 24 weeks (to Week 49). |
Pegvaliase (Palynziq) administered by subcutaneous injection. Dosing follows U.S. Prescribing Information and investigator judgement.
다른 이름들:
Oral methotrexate 15 mg administered once weekly during the Tolerability Period and the Combination Treatment Period.
다른 이름들:
|
|
실험적: Palynziq experienced
Individuals who have uncontrolled blood Phe > 600 μmol/L after ≥ 24 consecutive weeks of treatment with Palynziq, are on a current dose of ≥ 20mg/day and are unable to further dose escalate (Palynziq experienced). Participants will have a 4-week Screening Period. Participants will then have 24 weeks of concurrent MTX + Palynziq treatment (Combination Treatment Period): participants will be assessed for MTX tolerability during the first 4 weeks of MTX + Palynziq (MTX Tolerability Period) and then receive another 20 weeks of MTX + Palynziq. After completion of Week 24 (Combination Treatment Period), MTX will be discontinued for both cohorts and Palynziq only will continue for another 24 weeks (to Week 49). |
Pegvaliase (Palynziq) administered by subcutaneous injection. Dosing follows U.S. Prescribing Information and investigator judgement.
다른 이름들:
Oral methotrexate 15 mg administered once weekly during the Tolerability Period and the Combination Treatment Period.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in blood Phe levels from baseline to Week 25 and Week 49
기간: Baseline to Week 25 and Baseline to Week 49
|
To evaluate blood Phe response in adults with PKU co-administered Palynziq with MTX for 6 months |
Baseline to Week 25 and Baseline to Week 49
|
|
Anti-PEG IgG, IgM, anti-PAL IgG, IgM levels at Weeks 5, 9, 25, and 49
기간: Baseline to Week 5, Week 9, Week 25, and Week 49
|
To evaluate the ability of MTX to modulate the immune response to Palynziq in adults with PKU |
Baseline to Week 5, Week 9, Week 25, and Week 49
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of TEAEs
기간: Baseline through Week 49
|
To evaluate the safety of co-administration of Palynziq with MTX in adults with PKU. A TEAE is defined as any AE that newly appeared, increased in frequency, or worsened in severity following initiation of the study drugs (MTX or Palynziq) administration. Incidence of TEAEs will be defined as (number of TEAEs)/(total exposure time in person-years) *100 |
Baseline through Week 49
|
|
Trough Palynziq plasma PK
기간: Baseline through Week 49
|
To characterize the PK of Palynziq during co-administration with MTX in adults with PKU |
Baseline through Week 49
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in IgG-C3d CIC, C3, C4 levels from baseline to Weeks 9, 25, and 49
기간: Baseline to Weeks 9, 25, and 49
|
To evaluate formation of CIC and activation of complement pathway. Change from baseline to time t for each participant will be defined as (blood level at time t) - (blood level at baseline) |
Baseline to Weeks 9, 25, and 49
|
|
Percentage of participants in Cohort B that have escalated from dose at enrollment
기간: Baseline to Week 24 and Week 48
|
To evaluate ability to dose escalate in Cohort B participants following co-administration of Palynziq with MTX |
Baseline to Week 24 and Week 48
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Medical Director, MD, BioMarin Pharmaceutical
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- 165-401
- 2021-005058-27 (EudraCT 번호)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .